| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Haartman Institute and Helsinki University Central Hospital, Department of Pathology, University of Helsinki, Helsinki, Finland and 2 Cell and Cancer Biology Department, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
Requests for reprints: Erkki Hölttä, Haartman Institute and Helsinki University Central Hospital, Department of Pathology, University of Helsinki, P.O. Box 21, FIN-00014 Helsinki, Finland. Phone: 358-9-19126516; Fax: 358-9-19126675; E-mail: erkki.holtta{at}helsinki.fi.
S-adenosylmethionine decarboxylase (AdoMetDC) is a key enzyme in the synthesis of polyamines essential for cell growth and proliferation. Its overexpression induces the transformation of murine fibroblasts in both sense and antisense orientations, yielding highly invasive tumors in nude mice. These cell lines hence provide a good model to study cell invasion. Here, the gene expression profiles of these cells were compared with their normal counterpart by microarray analyses (Incyte Genomics, Palo Alto, CA, and Affymetrix, Santa Clara, CA). Up-regulation of the actin sequestering molecule thymosin ß4 was the most prominent change in both cell lines. Tetracycline-inducible expression of thymosin ß4 antisense RNA caused a partial reversal of the transformed phenotype. Further, reversal of transformation by dominant-negative mutant of c-Jun (TAM67) caused reduction in thymosin ß4 mRNA. Interestingly, a sponge toxin, latrunculin A, which inhibits the binding of thymosin ß4 to actin, was found to profoundly affect the morphology and proliferation of the AdoMetDC transformants and to block their invasion in three-dimensional Matrigel. Thus, thymosin ß4 is a determinant of AdoMetDC-induced transformed phenotype and invasiveness. Up-regulation of thymosin ß4 was also found in ras-transformed fibroblasts and metastatic human melanoma cells. These data encourage testing latrunculin Alike and other agents interfering with thymosin ß4 for treatment of thymosin ß4overexpressing tumors with high invasive and metastatic potential. (Cancer Res 2006; 66(2): 701-12)
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |